Estimated revenue and EBITDA for 2017
ADDvise Group AB’s revenues for the fourth quarter are estimated to SEK 62.3M (53.2). EBITDA adjusted for non-recurring incomes and costs amounted to SEK 4.5M (3.4). EBITDA amounted to SEK 2.8M (4.8).
Revenues during the fourth quarter have been lower than expected. This is partly due to a decline in order intake in the segment Lab’s project activities and partly due to a delivery delay caused by the closure of a production unit. In return, the order intake of the first quarter of 2018 has been strong, Rikard Akhtarzand, CEO of ADDvise Group, comments in regard to the preliminary outcome.
Revenue for the full year of 2017 is preliminary estimated at SEK 240M (195.3). EBITDA adjusted for non-recurring incomes and costs amount to SEK 15.2M (9.3). EBITDA amount to SEK 13.6M (18.1).
As communicated earlier, ADDvise Group has during the fourth quarter been burdened with non-recurring costs due to the refinancing of the company’s existing bond loan of approximately SEK 3.0M of which only SEK 0.9M impacts the cashflow.
The numbers are still preliminary and have not been reviewed by the auditors.
For further information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71
This information is by ADDvise required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on February 7th, 2018 at 08:45 CET.
About ADDvise Group
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. The Group has sales of about 250 MSEK. ADDvise shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, 08-503015 50, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.